The stock price of Evolent Health Inc (NYSE: EVH) has jumped by 12.95 compared to previous close of 7.57. Despite this, the company has seen a gain of 11.04% in its stock price over the last five trading days. seekingalpha.com reported 2025-05-09 that Evolent Health, Inc. (NYSE:EVH ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Seth Blackley – Chief Executive Officer John Johnson – Chief Financial Officer Conference Call Participants Jack Doney – UBS Matthew Gillmor – KeyBanc Ryan Daniels – William Blair Jessica Tassan – Piper Sandler Jeff Garro – Stephens Kyle Aikman – JPMorgan Matthew Shea – Needham Constantine Davides – Citizens Charles Rhyee – TD Cowen Daniel Grosslight – Citi David Larsen – BTIG Operator Welcome to the Evolent Earning Conference Call for the First Quarter Ended March 31, 2025. As a reminder, this conference call is being recorded.
Is It Worth Investing in Evolent Health Inc (NYSE: EVH) Right Now?
The 36-month beta value for EVH is also noteworthy at 0.88. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for EVH is 114.47M, and at present, short sellers hold a 14.61% of that float. The average trading volume of EVH on June 04, 2025 was 2.42M shares.
EVH’s Market Performance
The stock of Evolent Health Inc (EVH) has seen a 11.04% increase in the past week, with a -20.02% drop in the past month, and a 0.00% fall in the past quarter. The volatility ratio for the week is 6.66%, and the volatility levels for the past 30 days are at 6.06% for EVH. The simple moving average for the past 20 days is -0.60% for EVH’s stock, with a -44.75% simple moving average for the past 200 days.
Analysts’ Opinion of EVH
Many brokerage firms have already submitted their reports for EVH stocks, with Needham repeating the rating for EVH by listing it as a “Buy.” The predicted price for EVH in the upcoming period, according to Needham is $15 based on the research report published on January 10, 2025 of the current year 2025.
BTIG Research, on the other hand, stated in their research note that they expect to see EVH reach a price target of $29, previously predicting the price at $36. The rating they have provided for EVH stocks is “Buy” according to the report published on December 03rd, 2024.
Stephens gave a rating of “Equal-Weight” to EVH, setting the target price at $16 in the report published on November 08th of the previous year.
EVH Trading at -6.98% from the 50-Day Moving Average
After a stumble in the market that brought EVH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.58% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EVH starting from Holder Diane, who purchase 2,735 shares at the price of $9.33 back on Mar 06 ’25. After this action, Holder Diane now owns 70,584 shares of Evolent Health Inc, valued at $25,518 using the latest closing price.
McCarthy Daniel Joseph, the PRESIDENT of Evolent Health Inc, purchase 11,040 shares at $9.01 during a trade that took place back on Mar 06 ’25, which means that McCarthy Daniel Joseph is holding 389,004 shares at $99,470 based on the most recent closing price.
Stock Fundamentals for EVH
Current profitability levels for the company are sitting at:
- -0.01 for the present operating margin
- 0.14 for the gross margin
The net margin for Evolent Health Inc stands at -0.05. The total capital return value is set at -0.01. Equity return is now at value -10.99, with -4.11 for asset returns.
Based on Evolent Health Inc (EVH), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at 0.02. The debt to equity ratio resting at 0.93. The interest coverage ratio of the stock is -0.93.
Currently, EBITDA for the company is 84.85 million with net debt to EBITDA at 16.86. When we switch over and look at the enterprise to sales, we see a ratio of 0.68. The receivables turnover for the company is 5.57for trailing twelve months and the total asset turnover is 0.9. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.98.
Conclusion
In summary, Evolent Health Inc (EVH) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
